Exicure is a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the proprietary Spherical Nucleic Acid, or SNA, technology. Exicure’s lead therapeutic candidate, AST-005, an antisense SNA targeting tumor necrosis factor, or TNF, for the treatment of mild to moderate psoriasis. AST-005 is intended to be administered locally in a gel to psoriatic lesions. We believe this combines the benefits of specifically inhibiting validated targets without the potential safety issues associated with systemic therapies. We are also developing XCUR17, an antisense SNA targeting interleukin 17 receptor alpha, for mild to moderate psoriasis and AST-008, an SNA consisting of TLR9 agonist oligonucleotides, for the treatment of cancer.
Current report filing